However, the subset of 12 patients who received at least six cycles of maintenance therapy after induction included five patients with solid tumors in which PARP inhibition has been less well studied, including two with cutaneous squamous cell carcinoma, one of whom had a somatic pathogenic PALB2 alteration. This evidence concerns the gene PARP1 and cutaneous squamous cell carcinoma.